FDCA Carried Out “Absolutely Perfunctory, Premeditated And Peripheral Inquiry”: Dhanani To HC

Ahmedabad : Leader of Opposition in Gujarat Assembly, Paresh Dhanani, has termed the preliminary inquiry by the Food and Drug Control Administration (FDCA) that gave a clean chit to BJP state chief CR Paatil who distributed Covid drug from BJP office in Surat as “politically motivated and completely biased”.

In a rejoinder affidavit filed before the Gujarat High Court in connection with his petition on the “illegal distribution” of Remdesivir, Dhanani has relied on the Delhi High Court order that expressed dissatisfaction with the Drug Controller’s investigation and clean chit to BJP MP Gautam Gambhir and AAP MLAs of Delhi, who had distributed Fabiflu in Delhi during the peak of second wave of the Covid pandemic.

Navsari MP and Gujarat BJP president CR Paatil and MLA Harsh Sanghvi courted controversy in April when amid a dire shortage of the antiviral drug Remdesivir, Paatil had announced that 5,000 vials of the drug would be given free of cost to needy patients from Surat BJP office.

Contesting the clean chit given by Food and Drug Control Administration (FDCA) to Paatil and Sanghavi based on preliminary inquiry, a report of which was filed before the HC, Dhanani submitted that the FDCA has carried out “absolutely perfunctory, premeditated and peripheral inquiry inconsistent with the statutory obligation and devoid of their statutory functions and duties”.

Dhanani highlighted that his PIL raises two fundamental questions — one about two elected representatives belonging to BJP taking lead in purchasing, collecting, hoarding and distributing Remdesivir on charity from the BJP office with a political overtone and the second “abject failure on the part of Respondent 7 (FDCA)” in implementing Central government’s directives and failing to ensure that “no private individuals or association collects Remdesivir injection in large number and distributes the same in private initiative”. The matter has been posted for further hearing for August 4.

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise